These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 32753547)

  • 61. Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices.
    Velcheti V; Chandwani S; Chen X; Pietanza MC; Piperdi B; Burke T
    Immunotherapy; 2019 Dec; 11(18):1541-1554. PubMed ID: 31774363
    [No Abstract]   [Full Text] [Related]  

  • 62. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
    Kancharla H; Gundu N; Pathak N; Vandidassane I; Khurana S; Pushpam D; Jain D; Kumar S; Pathy S; Mohan A; Malik PS
    Curr Probl Cancer; 2020 Jun; 44(3):100550. PubMed ID: 31987521
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay.
    Evans M; O'Sullivan B; Hughes F; Mullis T; Smith M; Trim N; Taniere P
    Pathol Oncol Res; 2020 Jan; 26(1):79-89. PubMed ID: 30225784
    [TBL] [Abstract][Full Text] [Related]  

  • 65. First-line pembrolizumab efficacy in patients with advanced non-small cell lung cancer: A Bi-center retrospective, real-life experience study.
    Diker O; Olgun P
    J BUON; 2021; 26(3):844-852. PubMed ID: 34268944
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
    Lisberg A; Cummings A; Goldman JW; Bornazyan K; Reese N; Wang T; Coluzzi P; Ledezma B; Mendenhall M; Hunt J; Wolf B; Jones B; Madrigal J; Horton J; Spiegel M; Carroll J; Gukasyan J; Williams T; Sauer L; Wells C; Hardy A; Linares P; Lim C; Ma L; Adame C; Garon EB
    J Thorac Oncol; 2018 Aug; 13(8):1138-1145. PubMed ID: 29874546
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 68. PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer.
    Miyawaki E; Murakami H; Mori K; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Takahashi T
    Jpn J Clin Oncol; 2020 May; 50(5):617-622. PubMed ID: 32211792
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 70. First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis.
    Kim R; Keam B; Hahn S; Ock CY; Kim M; Kim TM; Kim DW; Heo DS
    Clin Lung Cancer; 2019 Sep; 20(5):331-338.e4. PubMed ID: 31164319
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.
    Wang H; Agulnik J; Kasymjanova G; Fiset PO; Camilleri-Broet S; Redpath M; Cohen V; Small D; Pepe C; Sakr L; Spatz A
    Lung Cancer; 2019 Jun; 132():36-38. PubMed ID: 31097091
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab.
    Freeman AT; Lesperance M; Wai ES; Croteau NS; Fiorino L; Geller G; Brooks EG; Poonja Z; Fenton D; Irons S; Ksienski D
    Curr Oncol; 2020 Apr; 27(2):76-82. PubMed ID: 32489249
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
    Cortellini A; De Giglio A; Cannita K; Cortinovis DL; Cornelissen R; Baldessari C; Giusti R; D'Argento E; Grossi F; Santoni M; Catino A; Berardi R; Sforza V; Rossi G; Antonuzzo L; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Follador A; Rastelli F; Chiari R; Gravara LD; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Pensieri MV; Russano M; Cantini L; Nigro O; Leonetti A; Bordi P; Minuti G; Landi L; De Toma A; Donisi C; Ricciardi S; Migliorino MR; Napoli VM; Leone G; Metro G; Banna GL; Friedlaender A; Addeo A; Ficorella C; Porzio G
    Thorac Cancer; 2021 Mar; 12(6):880-889. PubMed ID: 33527756
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
    Besse B; Garrido P; Cortot AB; Johnson M; Murakami H; Gazzah A; Gil M; Bennouna J
    Lung Cancer; 2020 Apr; 142():63-69. PubMed ID: 32114283
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial.
    Middleton G; Brock K; Savage J; Mant R; Summers Y; Connibear J; Shah R; Ottensmeier C; Shaw P; Lee SM; Popat S; Barrie C; Barone G; Billingham L
    Lancet Respir Med; 2020 Sep; 8(9):895-904. PubMed ID: 32199466
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer.
    Yang Z; Chen Y; Wang Y; Hu M; Qian F; Zhang Y; Zhang B; Zhang W; Han B
    Front Immunol; 2022; 13():807575. PubMed ID: 35237263
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.
    Rittberg R; Leung B; Shokoohi A; Pender A; Wong S; Al-Hashami Z; Wang Y; Ho C
    Curr Oncol; 2023 May; 30(6):5299-5308. PubMed ID: 37366885
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immunotherapy with toripalimab for lung adenocarcinoma in a real-world patient with an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 4: a case report.
    Xue Y; Zheng K; Xue J
    Ann Palliat Med; 2021 Sep; 10(9):10114-10123. PubMed ID: 34628932
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pembrolizumab monotherapy for non-small cell lung cancer (NSCLC): can patient stratification be improved in the UK Tayside population? A retrospective cohort study.
    Mander ES; Merrick CB; Nicholson HA; Lord HK; Ferguson MJ; Smith G
    BMJ Open; 2023 Nov; 13(11):e076715. PubMed ID: 37989364
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pembrolizumab Alone or With Chemotherapy for 70+ Year-Old Lung Cancer Patients: A Retrospective Study.
    Blasi M; Kuon J; Shah R; Bozorgmehr F; Eichhorn F; Liersch S; Stenzinger A; Heußel CP; Herth FJ; Thomas M; Christopoulos P
    Clin Lung Cancer; 2023 Nov; 24(7):e282-e290. PubMed ID: 37391339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.